Roche's Columvi win in earlier DLBCL faces questions over inconsistent patient survival data

Roche’s up-and-coming Columvi has demonstrated it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma. But the Swiss pharma still finds itself fielding questions about the bispecific drug’s market potential thanks to an imbalance noticed in the phase 3 data.